← Addex Therapeutics Ltd.

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Net Income — — — — — ($20.8m) ($10.6m) $7.1m ($6.7m)
Net Income From Continuing Operations — — — — — ($20.8m) ($10.6m) $7.1m ($6.7m)
Depreciation $15k $3k $334k $379k $348k $323k $306k $260k $8k
Depreciation Amortization Depletion — — — — — $323k $306k $260k $8k
Adjustments For Share-Based Payments — $2.3m $1.7m $1.2m $1.2m $3.7m $1.8m $503k —
Value of share-based services $800k $2.3m $1.7m $1.2m $1.2m $3.7m $1.8m $503k $71k
Earnings (Loss)es From Equity Investments — — — — — $0 $0 $2.2m $4.0m
Additional Financial Items
Adjustments For Finance Costs — $124k $235k $687k — — — — —
Adjustments For Undistributed Profits Of Associates — — — — — — — ($2.2m) —
General And Administrative Expense — $3.2m $5.0m $5.7m $5.8m $7.3m $5.0m $2.3m —
Payments Of Lease Liabilities Classified As Financing Activities — — $317k $367k $310k $288k $282k $74k —
Proceeds From Issuing Shares — $40.5m — — $10.2m — — — —
Net profit / (loss) for the period ($3.3m) ($1.6m) ($14.8m) ($12.9m) ($15.4m) ($20.8m) ($10.6m) $7.1m ($6.7m)
Net gain on Neurosterix Transaction — — — — — — — ($13.9m) ($114k)
Post-employment benefits $20k $20k $97k ($23k) ($150k) ($11k) ($63k) ($95k) ($7k)
Share of the net loss of associates — — — — — — — $2.2m $4.0m
Net gain related to lease modification — — — — — — ($318) ($3k) —
Finance cost / (income) net — — $235k $687k ($132k) $216k $313k ($100k) $38k
Decrease / (increase) in other financial assets ($5k) $3k ($6k) ($51k) $48k $14k $2k ($6k) $1k
Decrease / (increase) in trade and other receivables ($83k) ($77k) $155k $50k ($96k) ($252k) $307k $93k ($5k)
Decrease in contract asset — — — — ($160k) ($22k) $141k $41k —
Decrease / (increase) in prepayments — — ($521k) $222k ($617k) $845k $53k ($164k) $153k
Decrease / (increase) in other current assets — — — — — — — ($8k) $8k
Increase / (decrease) in payables and accruals ($212k) $1.1m $2.0m ($1.6m) $884k ($427k) ($613k) ($1.1m) $391k
Decrease in deferred income — — $331k ($244k) ($86k) — $324k ($38k) —
Consideration from Neurosterix Transaction — — — — — — — $5.1m $114k
Sale of treasury shares — — — — — — $2.4m $241k $1.2m
Cost paid on sale of treasury shares — — — — — — ($48k) ($26k) ($29k)
Cost of treasury share issuance — — — — — ($248k) ($54k) — ($6k)
Proceeds from the exercise of pre-funded warrants — — — — — $25k $36k — —
Costs paid on exercise of pre-funded warrants — — — — — ($576k) ($21k) ($36k) —
Principal element of lease payment — — ($317k) ($367k) ($310k) ($288k) ($282k) ($74k) ($7k)
Interest received — — $37k $35k $5k $29k $64k $9k —
Beginning Cash Position — — — — — $20.5m $7.0m $3.9m $3.3m
Cash Flow From Continuing Financing Activities — — — — — $3.1m $5.3m $105k $1.2m
Cash Flow From Continuing Investing Activities — — — — — $3k ($7k) $4.6m ($681k)
Change In Other Current Assets — — — — — $14k $2k ($14k) $9k
Change In Other Working Capital — — — — ($820k) — $324k ($38k) —
Change In Payables And Accrued Expense — — — — — ($427k) ($613k) ($1.1m) $391k
Change In Prepaid Assets — — — — — $845k $53k ($164k) $153k
Change In Receivables — — — — — ($274k) $447k $134k ($5k)
Change In Working Capital — — — — — $158k $214k ($1.2m) $549k
Changes In Account Receivables — — — — — ($252k) $307k $93k ($5k)
Changes In Cash — — — — — ($13.3m) ($2.7m) ($623k) ($1.7m)
End Cash Position — — — — — $7.0m $3.9m $3.3m $1.6m
Financing Cash Flow — — — — — $3.1m $5.3m $105k $1.2m
Free Cash Flow — — — — — ($16.4m) ($8.0m) ($5.4m) ($2.2m)
Gain Loss On Sale Of Business — — — — — $0 $0 ($13.9m) ($114k)
Gain Loss On Sale Of PPE — — — — ($127) $0 — — —
Investing Cash Flow — — — — — $3k ($7k) $4.6m ($681k)
Issuance Of Capital Stock — — — — — $1.7m $2.4m $241k $1.2m
Net Business Purchase And Sale — — — — — $0 $0 $5.1m $114k
Net PPE Purchase And Sale — — — — — ($581) ($7k) ($1k) $0
Operating Gains Losses — — — — — ($11k) ($63k) ($11.9m) $3.9m
Other Non Cash Items — — — — — $3.9m $2.1m $401k $108k
Pension And Employee Benefit Expense — — — — — ($11k) ($63k) ($95k) ($7k)
Proceeds From Stock Option Exercised — — — — — $2.3m $3.3m ($36k) $0
Purchase Of Business — — — — — $0 $0 ($473k) —
Purchase Of PPE — — — — — ($581) ($7k) ($1k) $0
Repurchase Of Capital Stock — — — — — ($3k) ($48k) ($26k) ($29k)
Sale Of Business — — — — — — $0 $5.1m $114k
Stock Based Compensation — — — — $1.2m $3.7m — — —
Profit or Loss — ($1.6m) ($14.8m) ($12.9m) ($15.4m) ($20.8m) ($10.6m) $7.1m —
Purchase of property, plant and equipment ($697) ($9k) ($28k) ($59k) ($32k) ($581) ($7k) ($1k) $0
Net Investment Purchase And Sale — — — — — $4k $0 $0 ($795k)
Purchase Of Investment — — — — — — $0 $0 ($795k)
Sale Of Investment — — — — $1k $4k $0 $0 —
Net cash from/(used in) investing activities ($697) ($56k) ($43k) ($59k) ($30k) $3k ($7k) $4.6m ($681k)
Net Issuance Payments Of Debt — — — — — ($288k) ($282k) ($74k) ($7k)
Net Long Term Debt Issuance — — — — — ($288k) ($282k) ($74k) ($7k)
Long Term Debt Payments — — — — — ($288k) ($282k) ($74k) ($7k)
Repayment Of Debt — — — — — ($288k) ($282k) ($74k) ($7k)
Common Stock Issuance — — — — — $1.7m $2.4m $241k $1.2m
Net Common Stock Issuance — — — — — $1.7m $2.3m $215k $1.2m
Common Stock Payments — — — — — ($3k) ($48k) ($26k) ($29k)
Cash Dividends Paid — — — — — $0 $0 $0 $0
Net Other Financing Charges — — — — — ($523k) $10k $9k ($6k)
Net cash from financing activities $3.4m $37.4m ($464k) $46k $16.4m $3.1m $5.3m $105k $1.2m
Effect Of Exchange Rate Changes — — — — — ($196k) ($357k) $100k ($35k)
Decrease in cash and cash equivalents $1.2m $39.1m ($10.0m) ($12.2m) $1.7m ($13.3m) ($2.7m) ($623k) ($1.7m)
Cash and cash equivalents at beginning of the year $2.6m $41.7m $31.5m $18.7m $20.5m $7.0m $3.9m $3.3m $1.6m
Exchange difference on cash and cash equivalents ($45k) $10k ($144k) ($649k) $122k ($196k) ($357k) $100k ($35k)
Change In Cash Supplemental As Reported — — — — — ($13.3m) ($2.7m) ($623k) ($1.7m)
Interest Paid Classified As Financing Activities ($171) $134k $129k $70k $63k $49k $22k $9k ($2k)

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.